If you were at the Advanced Therapies Week in Miami from January 17-20, you learned first-hand about our newest catalog CRISPR protein, Eureca-V™ Nuclease. But what exactly is Eureca-V? In short, the core technology for Eureca-V is the proprietary MAD7® nuclease developed by Inscripta®. Aldevron and Inscripta have partnered to make this protein broadly available to the therapeutic, diagnostic, and agricultural research markets.
NanoplasmidTM. We’ve been discussing this topic quite a bit recently, and now our latest whitepaper brings you an in-depth examination of our novel Next-Generation plasmid technology. The etiology of its name, “nano,” originates from its purposefully designed “small” backbone of around 500 base pairs (bp) as compared to traditional plasmids that often exceed 2000 bp. This reduced backbone size is a direct result of removing prokaryotic and antibiotic-resistance genes used to select transformed bacteria and propagate a vector.
Genomic medicine field has progressed in leaps and bounds these last few years, and at the 3rd Annual CRISPR 2.0 conference, it was wonderful to again connect in person with colleagues to discuss those advances. It was a great opportunity to listen and learn from a prestigious lineup of gene editing experts from across the industry.
As one of the most significant discoveries in gene and cell therapy, CRISPR/Cas9 genome editing systems continue to evolve. In this webinar, “Genome Editing Tools: Beyond Discovery,” Aldevron experts Dr. Jim Williams and Max Sellman detail innovative tools to support gene editing clinical programs, highlighting Nanoplasmids as an HDR template paired with Cas9 nucleases in CAR-T applications.
I’m always grateful for the chance to hear the latest results from drug developers in the CRISPR space. That’s why it was a huge bonus to have a world class cell and gene therapy conference just fifteen minutes down the road from Aldevron Madison in September!
When it comes to gene editing technology, there are few meetings as valuable for us and our collaborators as the annual CRISPR meeting. Academic in focus and highly technical in nature, the 2022 edition of this event came to Boston, packing more than 40 lectures and 120 posters into a rapid-fire, three-day learning experience.
